Send the completed form
to [email protected]om
Send the completed form
to [email protected]
Direct your patients to visit
cibinqo.ca for more information
Send the completed form
to [email protected]om
Direct your patients to visit
inflectra.ca for more information
Send the completed form
to [email protected]m
Direct your patients to visit
ruxience.ca for more information
Send the completed form
to [email protected]om
Direct your patients to visit
xeljanz.ca for more information
PrABRILADA® (adalimumab)
For more information:
Please consult the Product Monograph at https://www.pfizer.ca/en/our-products/abrilada-adalimumab-injection for important information relating to other indications, contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-800-463-6001.
PrCIBINQO® (abrocitinib)
For more information:
Please consult the Product Monograph at https://www.pfizer.ca/en/our-products/cibinqo-abrocitinib-tablets for important information relating to contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-800-463-6001.
PrINFLECTRA® (infliximab)
For more information:
Please consult the Product Monograph at https://www.pfizer.ca/en/our-products/inflectra-infliximab for important information relating to other indications, contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-800-463-6001.
PrRUXIENCE® (rituximab)
For more information:
Please consult the Product Monograph at https://www.pfizer.ca/en/our-products/ruxience-rituximab-injection for important information relating to contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-800-463-6001.
PrXELJANZ® XR / PrXELJANZ® (tofacitinib)
For more information:
Please consult the Product Monograph at https://www.pfizer.ca/en/our-products/xeljanz-tofacitinib and an Important Safety Information Advisory available at https://recalls-rappels.canada.ca/en/alert-recall/health-canada-safety-review-finds-link-between-use-xeljanz-and-xeljanz-xr-tofacitinib for important information relating to other indications, contraindications, warnings, precautions, adverse reactions,interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-800-463-6001.